Letters
Author's reply I appreciate Dr Crowley's comments. At the time of writing I had seen one paper on lactic acidosis from Chattha et al. ' published as a brief report. Subsequently, there have been a series of letters and additional papers published and I would agree that specific mention should now be made of lactic acidosis in HIV disease. In the absence of sepsis and hypoxia, thiamine deficiency and zidovudine therapy should be considered as possible causes. Indeed, the latest data sheet on zidovudine from Wellcome has added the following advice: 'Treatment with Retrovir should be suspended in the setting of rapidly elevating aminotransferase levels, progressive hepatomegaly, or metabolic/lactic acidosis of unknown aetiology'. 2 The value of lactate dehydrogenase (LDH) measurements is not universally accepted, chiefly because the lack of tissue specificity may make interpretation difficult and isoenzyme studies are not readily available. We started measuring total LDH, not for its clinical value, but as a requirement for drug trials. While I agree that levels are usually increased in Pneumocystis carinii pneumonia (PCP), one survey concluded that it was a poor screening test in patients without dyspnoea and was no substitute for microbiological studies." However, I would certainly accept that very high levels can be helpful in the diagnosis of non-Hodgkin's lymphoma. and assumed that the fetal loss rate as a result of amniocentesis should be no greater than 10,10.
S G BALL
Nicolaides et at,' showed that in a centre with experienced personnel, the fetal loss rate due to early amniocentesis was 5·3-5·90,10, and that due to chorionic villus sampling (CVS) was 1· 2-2' 3010. Other studies" have reported the risk of pregnancy failure due to CVS as up to 4·6%. One must then consider that both of these reports relate to early amniocentesis and CVS in expert centres, and the likely result of dissemination of the techniques to all hospitals will be a worsening of outcomes. Clearly, if a suitable diagnostic test is not available, early screening is not acceptable. However, from both the safety criteria of the RCOG report and the reactions of women being offered Down's screening (personal observation) a fetal loss rate approaching 5% is also unacceptable. In conclusion, therefore, we must exercise extreme care before advocating earlier Down's syndrome screening until a safe diagnostic test becomes widely available.
